{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001485","form_type":"8-K","ticker":"CCRN","cik":"0001141103","company_name":"CROSS COUNTRY HEALTHCARE INC","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.738311+00:00","generated_at":"2026-06-22T12:08:43.154940+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cross Country Healthcare Q3 revenue $636.1M (+70% YoY); guides Q4 revenue $590-600M","bullets":["Revenue $636.1M (+70% YoY, -16% sequential); net income $34.8M ($0.93 diluted EPS).","Adjusted EBITDA $63.8M (10.0% margin), down 24% sequentially from $83.5M.","Repurchased 1M shares for $24.3M at avg $23.97; $87.2M remaining under $100M buyback.","Q4 guidance: Revenue $590-600M (down 6-8% YoY); Adjusted EPS $0.85-$0.95.","Cash from ops $140.6M; closed Mint and Lotus locum tenens acquisitions in October."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001485","json":"https://secwatch.observer/filing/0001157523-22-001485.json","markdown":"https://secwatch.observer/filing/0001157523-22-001485.md","text":"https://secwatch.observer/filing/0001157523-22-001485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/0001157523-22-001485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/a52957594.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:08:43.154940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c51aed2f3ba8f2f03a1e115ac5b1a76f58da6926","claim":"CROSS COUNTRY HEALTHCARE INC reported the third quarter ended September 30, 2022 results: revenue $636,098, net income $34,793, EPS $0.93.","evidence_excerpt":"September 30, 2022. SELECTED FINANCIAL INFORMATION: Variance Variance Q3 2022 vs Q3 2022 vs Dollars are in thousands, except per share amounts Q3 2022 Q3 2021 Q2 2022 Revenue $ 636,098 70 % (16) % Gross profit margin* 22.6 % 20 bps — bps Net income attributable to common stockholders $ 34,793 48 % (34) % Diluted EPS $ 0.93 $ 0.31 $ (0.47) Adjusted EBITDA* $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1141103/000115752322001485/0001157523-22-001485-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$636,098"},{"label":"Net income","value":"$34,793"},{"label":"EPS","value":"$0.93"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}